Google DeepMind and its drug-discovery affiliate Isomorphic Labs have set out a shared approach to "bioresilience," positioning their protein-structure and molecular-design AI as tools to strengthen defenses against biological threats and accelerate the search for new medicines. The move ties together two of Alphabet's most closely watched biology efforts: DeepMind's AlphaFold structure-prediction work and Isomorphic Labs' proprietary drug-design engine.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.